PharmaFocus Today – Page 215 – media

Secretary of state sets out priorities for UK health and social care systems

The commitments will make health systems faster, simpler and fairer for patients Health and social care secretary Victoria Atkins has set out new priorities to improve the health and social care system in the UK. The new commitments intend to make the health and social care system faster, simpler and fairer for patients. As healthcare systems approach the winter season, Atkins has committed to ensuring that health and social care services are faster for patients by making it easier to get treatment locally, improving A&E performance and cutting waiting lists. She commits to making systems simpler for patients and staff with joined-up integrated care and reducing bureaucracy by giving them the latest technology to free up their time to care for patients. Furthermore, Atkins committed to making systems fairer by ensuring that children are protected from health harms; health outcomes are not determined by where people live; the government supports ...
- Source: drugdu
- 93
- December 9, 2023
Study reveals motor neuron region is affected in ALS

The neurological condition currently affects one in 300 people in the UK King’s College London (KCL) researchers have revealed a mechanism behind dysregulated neuronal activity, a key pathology of amyotrophic lateral sclerosis (ALS). The new study, published in Cell Reports, identifies the axon initial segment (AIS) as the region that drives abnormal regulation of neuronal activity in ALS. Affecting one in 300 people in the UK, ALS, or motor neurone disease, is a neurological disorder that progressively destroys neurons in the brain and spinal cord. Researchers found that the molecular, structural and functional changes in the AIS, the region where electrical signals in neurons initiate, cause abnormal neuronal excitability. In the study, researchers examined two of the most common genetic causes of AIS mutations in the genes, TDP-43 and C9ORF72. In ALS, the electrical signalling in motor neurons initially increases during the early stages of the condition and progressively becomes ...
- Source: drugdu
- 95
- December 9, 2023
Q&A With UCB’s Camille Lee on New Psoriasis Medication Approval

Don Tracy, Associate Editor UCB executive speaks on recent FDA approval of Bimzelx. In an interview with Pharm Exec associate editor Don Tracy, Camille Lee, VP, head of US immunology, UCB, speaks about the company’s recent FDA approval for Bimzelx, a treatmemt for psoriasis. Q&A With UCB’s Camille Lee on New Psoriasis Medication Approval 1 Play Video Pharm Exec: Generally speaking, how far does UCB’s work in psoriasis span? Lee: UCB started its research work in psoriasis over a decade ago. Through that work, we have two assets available. Most recently and most directly related to UCB’s work is our recent approval of Bimzelx. That approval has been specifically first and foremost in the area of psoriasis. It is the first and only approved treatment that is selectively targeted to directly inhibit the IL-17A and IL-17F, which are two key things causing the inflammation of psoriasis. That product has been ...
- Source: drugdu
- 107
- December 8, 2023
What Excites One Mayo Clinic Radiologist About AI in Her Field

Dr. Wendaline VanBuren, a radiology chair at Mayo Clinic, thinks that AI is in the beginning stages of improving radiologists’ workflows. Some of the most developed radiology AI research projects at Mayo center on image segmentation and 3D printing, she said. In the future, she’s excited to see more tools that aid radiologists in triage and lesion measurement. By KATIE ADAMS Radiology, like most physician specialties, is dealing with a labor shortage driven by burnout and an aging workforce. AI is often heralded as something that can help solve these workforce problems, but a lot of AI deployment in radiology is still in its iterative phase, said Dr. Wendaline VanBuren, chair of the gynecological imaging section within the division of abdominal radiology at Mayo Clinic. Dr. VanBuren made this remark last week during an interview at RSNA 2023, the annual radiology and medical imaging conference in Chicago. While AI still ...
- Source: drugdu
- 104
- December 8, 2023
The long-term care crisis

For many in America, especially people in the middle class, old age is a daily struggle to keep up with basic activities. For some, the trials of dementia add to the emotional and financial burden for loved ones and caregivers. Long-term care options — assisted living, home care, or full-time family care — are costly, complex, and often inadequate. Jordan Rau, KFF Health News senior correspondent, moderated a Zoom event Dec. 5 about “Dying Broke,” an investigative project undertaken with The New York Times and Times reporter Reed Abelson about America’s long-term care crisis. Panelists shared their lived experiences of caregiving. The event was hosted by KFF Health News and the John A. Hartford Foundation. Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy ...
- Source: drugdu
- 90
- December 8, 2023
Medicine for a Broken System

Our teenaged son never misses an opportunity to tease me when I do something he deems old-fashioned. “Hey Mom and Dad,” he’ll ask, “what was it like back in the 1900’s?” While our son’s question is rhetorical, it did get us thinking about how much has changed in our field of study: medicine. At the start of the 1900s, the practice of medicine was based on a “symptom model” where care was sought when patients felt poorly and would see a doctor who would try to make them feel better. Addressing symptoms is important, but in the 21st century, many major medical problems do not present symptoms before they cause trouble. No one has ever said, “I feel I may have a stroke soon,” or “I think I may break a hip.” So, what about age itself? Is aging symptomatic? Is aging a disease? Can aging be fixed? In cardiology, ...
- Source: drugdu
- 96
- December 8, 2023
IGM jettisons workforce and blood cancer programme to refocus pipeline

IGM Biosciences plans to axe 22% of its workforce, becoming the latest company to downsize in a bid to free cash resources. Amid the layoffs, the US-based biotechnology company will also reprioritise its pipeline, discontinuing operations for all haematologic oncology and targeted cytokine product development while doubling down on its efforts in the clinical development of T cell engagers for autoimmune diseases and a DR5 agonist for colorectal cancer. IGM expects the restructuring to extend the company’s cash runway into Q2 2026. The restructuring comes less than a month after the company said it anticipated an increase in headcount to support the research and development of its pipeline candidates, citing its intent to advance and expand its antibody product pipeline, in its 13 November 10-Q filing. In the same filing, the company acknowledged that it had significant net losses to date and that achieving profitability sufficient enough to offset the ...
- Source: drugdu
- 100
- December 8, 2023
Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case

After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. The case stems back to 2017 and has its roots in Novartis’ Tafinlar, a melanoma therapy that the company acquired from GSK after a 2015 asset swap. Daiichi’s former subsidiary Plexxikon, which makes melanoma treatment Zelboraf, alleged that GSK scientists only gathered the knowledge necessary to develop the rival drug after consulting with Plexxikon for talks about a partnership that never came to fruition. Plexxikon’s patents date back to 2005, while GSK filed its first patent application on the drug in 2008, Plexxikon said. In 2021, a Northern California jury ruled in favor of Plexxikon, determining that Novartis stepped on two of the Daiichi subsidiary’s patents. Novartis was ordered to pay Daiichi’s subsidiary 9% royalty payments on future Tafinlar sales until certain Zelboraf patents expire ...
- Source: drugdu
- 104
- December 8, 2023
Novartis’ Fabhalta approved by FDA as first oral monotherapy for rare blood disease PNH

Novartis’ Fabhalta (iptacopan) has been approved by the US Food and Drug Administration (FDA) as the first oral monotherapy for adults with paroxysmal nocturnal haemoglobinuria (PNH), a rare blood disease affecting approximately ten to 20 people per million worldwide. PNH patients have an acquired mutation that causes them to produce red blood cells susceptible to premature destruction by the complement system, which can cause anaemia, thrombosis, fatigue and other symptoms that can impact quality of life. The disease has a significant unmet need, Novartis reports, with a large proportion of patients on anti-C5 treatment remaining anaemic and dependent on blood transfusions. Fabhalta is a factor B inhibitor of the immune system’s complement pathway and offers an alternative to therapies that need to be delivered by infusion or injection. Victor Bultó, president US, Novartis, described the approval as an “extraordinary moment” for the PNH community. “This new, effective oral medicine may ...
- Source: drugdu
- 103
- December 8, 2023
AstraZeneca and generative AI company Absci enter $247m oncology partnership

AstraZeneca (AZ) and Absci have entered into a collaboration agreement worth up to $247m to develop an artificial intelligence (AI)-designed antibody drug for a specified oncology target. The partnership will combine AZ’s capabilities in oncology research and development with Absci’s Integrated Drug Creation platform, which the generative AI company says “unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimising multiple drug characteristics important to both development and therapeutic benefit”. The agreement includes an upfront commitment from AZ as well as research and development funding, milestone payments and royalties on product sales. Puja Sapra, senior vice president of biologics engineering and oncology targeted delivery at AZ, said: “This collaboration is an exciting opportunity to utilise Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology.” Absci outlines that its approach “overcomes the limits of traditional drug discovery”. ...
- Source: drugdu
- 122
- December 8, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.